Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C34H34N4O4.C6H14N4O2.Fe |
Molecular Weight | 792.704 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 2 |
SHOW SMILES / InChI
SMILES
[Fe++].N[C@@H](CCCNC(N)=N)C(O)=O.CC1=C(CCC(O)=O)C2=CC3=NC(=CC4=C(C=C)C(C)=C(N4)C=C5N=C(C=C1N2)C(C)=C5C=C)C(C)=C3CCC(O)=O
InChI
InChIKey=BONOMRJXDYBFLR-FCYLROMBSA-N
InChI=1S/C34H34N4O4.C6H14N4O2.Fe/c1-7-21-17(3)25-13-26-19(5)23(9-11-33(39)40)31(37-26)16-32-24(10-12-34(41)42)20(6)28(38-32)15-30-22(8-2)18(4)27(36-30)14-29(21)35-25;7-4(5(11)12)2-1-3-10-6(8)9;/h7-8,13-16,36-37H,1-2,9-12H2,3-6H3,(H,39,40)(H,41,42);4H,1-3,7H2,(H,11,12)(H4,8,9,10);/q;;+2/b25-13-,26-13-,27-14-,28-15-,29-14-,30-15-,31-16-,32-16-;;/t;4-;/m.0./s1
Molecular Formula | C6H13N4O2 |
Molecular Weight | 173.193 |
Charge | -1 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | Fe |
Molecular Weight | 55.845 |
Charge | 2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C34H31N4O4 |
Molecular Weight | 559.6343 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Heme arginate (or haem arginate, brand name NORMOSANG) has been used to treat acute porphyrias. NORMOSANG successful uses in Europe and South Africa, but it has not been approved for use in the United States. Heme arginate consists of haem complexed with the amino acid arginine. This forms a stable compound. Haem arginate works by replenishing haem stores within the body. By negative feedback, haem arginate inhibits the initial rate-limiting enzyme of the haem synthetic pathway, ALA synthase (Delta-aminolevulinic acid dehydratase). The most frequent complication is phlebitis at the site of infusion. This can be reduced by giving the infusion of haem arginate in a protein buffer such as stabilized human serum or human serum albumin. In addition, there were studies, which revealed, that heme arginate induced beneficial effects in some myelodysplastic syndrome (MDS) patients and had very few side effects. In addition was shown, that heme arginate could be useful in the treatment of thalassemia intermedia.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2882011
Curator's Comment: Known to be CNS non-penetrant in rabbite. Human data not available
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P13196 Gene ID: 211.0 Gene Symbol: ALAS1 Target Organism: Homo sapiens (Human) |
|||
Target ID: P22557 Gene ID: 212.0 Gene Symbol: ALAS2 Target Organism: Homo sapiens (Human) |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Normosang Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Up-regulation of CYP2A5 expression by porphyrinogenic agents in mouse liver. | 1995 Apr |
|
Heme oxygenase substrates acutely lower blood pressure in hypertensive rats. | 1996 Sep |
|
The effects of inhibition of haem biosynthesis by griseofulvin on intestinal iron absorption. | 2004 Apr |
|
[Acute intermittent porphyria and oral contraception. Case report]. | 2006 Mar |
|
Heme arginate suppresses cardiac lesions and hypertrophy in deoxycorticosterone acetate-salt hypertension. | 2009 Jul |
|
Treatment with heme arginate alleviates adipose tissue inflammation and improves insulin sensitivity and glucose metabolism in a rat model of Human primary aldosteronism. | 2012 Dec 15 |
Patents
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 19:21:58 GMT 2023
by
admin
on
Fri Dec 15 19:21:58 GMT 2023
|
Record UNII |
R1B526117P
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
79893
Created by
admin on Fri Dec 15 19:21:58 GMT 2023 , Edited by admin on Fri Dec 15 19:21:58 GMT 2023
|
||
|
FDA ORPHAN DRUG |
9185
Created by
admin on Fri Dec 15 19:21:58 GMT 2023 , Edited by admin on Fri Dec 15 19:21:58 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
R1B526117P
Created by
admin on Fri Dec 15 19:21:58 GMT 2023 , Edited by admin on Fri Dec 15 19:21:58 GMT 2023
|
PRIMARY | |||
|
SUB14045MIG
Created by
admin on Fri Dec 15 19:21:58 GMT 2023 , Edited by admin on Fri Dec 15 19:21:58 GMT 2023
|
PRIMARY | |||
|
100438-92-4
Created by
admin on Fri Dec 15 19:21:58 GMT 2023 , Edited by admin on Fri Dec 15 19:21:58 GMT 2023
|
PRIMARY | |||
|
C048849
Created by
admin on Fri Dec 15 19:21:58 GMT 2023 , Edited by admin on Fri Dec 15 19:21:58 GMT 2023
|
PRIMARY | |||
|
100000077902
Created by
admin on Fri Dec 15 19:21:58 GMT 2023 , Edited by admin on Fri Dec 15 19:21:58 GMT 2023
|
PRIMARY | |||
|
26506
Created by
admin on Fri Dec 15 19:21:58 GMT 2023 , Edited by admin on Fri Dec 15 19:21:58 GMT 2023
|
PRIMARY | RxNorm | ||
|
HEME ARGINATE
Created by
admin on Fri Dec 15 19:21:58 GMT 2023 , Edited by admin on Fri Dec 15 19:21:58 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |